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Neurological disordersEpigeneticmodulations play essential roles in diverse biological processes. During the past several years, DNAde-
methylation has beendiscovered in embryonic and postnatal development. Although somepotential functions of
DNA methylation have been demonstrated already, many questions remain in terms of unveiling the role of
5hmC;whether it serves eithermerely as an intermediate of DNAdemethylation or as a stable epigeneticmarker.
5-hydroxymethylcytosine (5hmC) is proved to be not merely serving as an intermediate of DNA demethylation,
but also acts as a stable epigenetic marker. This review summarizes the current knowledge of the function of
5hmC in brain with the focus on the neuronal activity, neurodevelopment, aging, and neurological diseases.
© 2014 Elsevier Inc. All rights reserved.1. Introduction
DNA methylation at the ﬁfth carbon of cytosine (5-methylcytosine,
5mC) is the best studied epigenetic modiﬁcation, and plays pivotal
roles in multiple biological processes including the regulation of chro-
matin structure, gene imprinting, X chromosome inactivation, and ge-
nomic stability, and this process is implicated in development, aging,
and diseases through regulating tissue-speciﬁc gene expression [1].
The enzymes that establish andmaintain the landscape of DNAmethyl-
ation, namely the DNA methyltransferases (Dnmts), have three family
members, Dnmt1 (preserving the methylation), Dnmt3A and 3B (de
novo methyltransferase) and a regulatory subunit Dnmt3L [2]. DNA
methylation displays a dynamic pattern during embryonic develop-
ment and Dnmts absence has been shown to induce the lethal effects
during these critical developmental periods [3,4]. In the neuronal sys-
tem, the depletion of Dnmts not only impaired memory, but also led
to inhibited neurogenesis in adult brain [5–7]. Methylated DNA can be
recognized by a range of speciﬁc “readers”, such asmethyl-CpG binding
protein 2 (MeCP2) and methyl-CpG-binding domain proteins 1–4
(Mbd1–4) [8,9]. The deletion of MeCP2 causes the neurodevelopmental
disorder Rett syndrome, andMbd1 absence induces an autism-like phe-
notype [10,11]. MeCP2 and Mbd1 also regulate adult neurogenesis
through interacting with microRNA pathway [12,13]. Collectively,
these results indicate the essential roles of DNAmethylation in both de-
velopment and function of brain.lege of Life Sciences, Zhejiang
58, China.Although DNA methylation has been regarded as a highly
stable marker for the long time, the chasing of a candid DNA
demethylase has never stopped. In 1953, a novel DNA modiﬁcation
form, 5-hydroxymethylcytosine (5hmC), was identiﬁed in the T-even
bacteriophage [14]. Later on, 5hmC was further discovered in mamma-
lian genomes [15]. However, the mechanisms and proteins responsible
for generating this marker remained elusive until 2009. Rao's and
Heintz's groups conﬁrmed the existence of 5hmC in mammalian brain
and uncovered the real player for DNA demethylation, the Ten-eleven
translocation (Tet) gene; Tet1 [16,17]. They discovered that Tet1 is a
2-oxoglutarate (2OG)- and Fe (II)-dependent enzyme, and can catalyze
the conversion of 5mC to 5hmC [16,17]. Later, other studies identiﬁed
more Tet family members, Tet2 and Tet3, which share a high degree
of homology within their C-terminal catalytic domain and all of which
can catalyze the conversion of 5mC to 5hmC [18,19]. Furthermore,
studies revealed that the Tet protein can further oxidize 5hmC to
5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) [18,19], adding
a completely new perspective on the uncovering complexity of the
potential function of 5hmC mediated epigenetic regulation during
development.
Genome-wide studies revealed that 5hmC could enrich in gene bod-
ies, promoters, and distal regulatory regions [20–23]. The enrichment of
5hmC is positively correlated with transcript level, which might be
achieved through the interaction with histone modiﬁcation. Mean-
while, cell- and tissue-speciﬁc features of 5hmC were also revealed
[17,20,24–27]. Upon ES cell differentiation, global 5hmC decreases;
however, overall 5hmC increases during neuronal development. 5hmC
is approximately 10-fold more abundant in neurons than other tissues
or ESCs [17,20], suggesting that 5hmC might have a signiﬁcant role in
brain, as an important and stable epigenetic marker. Here, we reviewed
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function of 5hmC in neuronal activity, neurodevelopment, aging, and
neurodevelopmental and neurodegenerative diseases. See also reviews
by the Preifer, Marques and Tang labs in this Special Issue.
2. DNA demethylation in neuronal activity and memory
Neuronal activation could induce the alteration of the neuronal
methylome including demethylation and de novo methylation, which
consequentially modulated gene expression [28,29]. Activity-modiﬁed
CpGs, usually low-density CpGs, are enriched in neuronal genes and
preferentially associated with alternative splicing variants [28]. Active
genes in neurons display the enrichment of 5hmC in gene bodies [30].
Even in different types of neuronal cells, such as Purkinje cells (PCs),
granule cells (GCs) and the terminally differentiated Bergmann glial
cells (BGs), 5hmC displays cell type-speciﬁc distribution in genome
[30], indicating potential roles of 5hmC in the process of cell identity de-
termination [20,27,30].
Two groups found that over-expression of Tet1 resulted in the de-
methylation of the promoter IX of Bdnf (brain-derived neurotrophic
factor) (Bdnf IX), and a brain-speciﬁc promoter of Fgf1 (ﬁbroblast
growth factor 1) (Fgf1B), two loci exhibiting neuronal activity-induced
active DNA demethylation in the adult dentate granule cells [31,32].
The inhibition of Tet1 could repress neuronal activity induced promoter
demethylation of Bdnf IX and Fgf1B, and the expression of these two
genes [31]. An earlier study found that Tet1 depletion led to impaired
adult neurogenesis and poor learning and memory [33]. Later, another
group found that although Tet1 KO mice display normal memory
formation, thesemice showed speciﬁc impairments in extinction learn-
ing and abnormally enhanced long-term depression [34]. The over-
expression of both Tet1 and its catalytic inactivation form impaired
long-term memory formation while no effect on short-term memory
[32]. Of note, the expression of Tet1, but not Tet2 and Tet3, is also
regulated by neuronal activity [32]. These results indicated that Tet-
mediated 5hmC pathway is normally required for speciﬁc typememory
formation and extinction. Meanwhile, these discoveries raise the possi-
bility that Tet members play differential functions in brain, and their
function could be catalytic activity independent.
3. DNA demethylation in neurodevelopment
The studies from the developing embryo and embryonic stem cells
have indicated the dynamic features of 5hmC during development
[35,36]. Hahn et al. found an acquirement of 5hmC during embryonic
brain development [27]. Further, 5hmC also increased globally in
different brain regions during postnatal neuronal development [20].
The manipulation of the Tet enzymes could lead to the alteration of
5hmC, which resulted in speciﬁc phenotypes [27]. During postnatal
brain development, DNAmethylation in non-CG contexts (CH) accumu-
lates during brain development and becomes the dominant form of
methylation in adult brain [37]. Non-CG methylation was usually de-
pleted in expressed genes, which is opposite to that observed in embry-
onic stem cells [37]. Furthermore, the rapid accumulation of CH
methylation in neurons during postnatal development is in parallel
with synaptogenesis [37]. In Tet2 mutant mice, some regions become
hypermethylated and CG methylation was signiﬁcantly increased [37].
Considering all three Tet genes are expressed in brain, it is possible
that individual Tet genes could have different functions in different re-
gions of the brain and at different ages.
During neuronal development, 5hmC highly enriched in active ge-
nomic regions, and gene bodies of highly expressed genes while the
lowly expressed genes showed intragenic depletion of 5hmC [37–40].
Meanwhile, developmentally down-regulated geneswere accompanied
by a loss of 5hmC enrichment. The enhancers of the regions becoming
hypomethylated gained active histone modiﬁcations including
H3K4me1 and H3K9ac; consistently, the regions acquiring methylationlost these active histonemodiﬁcations [37] (Fig. 1). All these studies in-
dicate intragenic 5hmC levelswhichmight be associatedwith transcrip-
tional activity.
Previous studies had noted that modiﬁed cytosine changed at the
exon–intron boundary of genes with the intensity being higher on the
exonic side, which did not distinguish 5hmC and 5mC due to technical
limitations [41,42]. Khare et al. found 5hmC uniquely marked the
exon-intron boundaries in mammalian brain but not in non-neural or-
gans [40]. Exonic 5hmC in multi-exon genes was higher than that of
intronless or single-exon genes; furthermore, 5hmC densities were
lower in alternatively spliced exons relative to constitutive exons [40],
indicating the potential function of 5hmC in splicing regulation.
4. DNA demethylation in aging
The brain aging process is characterized by increased DNA damage,
distinct structural alternations, synaptic dysfunction and cognitive de-
cline, with some regions including neocortical and hippocampal net-
works showing age-related pathology. Region-speciﬁc alterations in
gene expression, occurring in the aging brain, including the down regu-
lation of genes related to synaptic plasticity and neurotrophic support,
are likely to be susceptible to epigenetic modulation.
The alteration of DNA methylation has been indicated during brain
aging process, which involves in the decline of cognitive function [43].
Our previous study found that 5hmC globally increased during aging
process (6-week to 1-year) in cerebellum regions, but displayed slight
decrease in the hippocampus [20]. 5hmC also exhibited dynamic fea-
tures during this process, suggesting that 5hmCmodiﬁcation at speciﬁc
loci could play roles in the aging process [20]. A further two studies
found that global 5hmC also increased in the more aged hippocampus
such as at two years of age [44,45]. More detailed studies should be per-
formed to uncover 5hmC changes at later stages of aging.
Oxidative stress is one of the essential factors contributing to brain
aging, andmitochondria are the primary source of free radicals and neu-
rodegeneration. One isoform of Dnmt1, mtDnmt1, is the only member
of Dnmt family which exists in mitochondria and is essential for
mtDNAmethylation. The expression of mtDnmt1 is regulated by factors
that respond to oxidative stress stimuli [46]. Besides 5mC, 5hmC was
also found inmtDNA, suggesting that 5hmC couldmodifymitochondria
genome and regulate its function [46]. These discoveries link 5-hmC to
oxidative stress, and point out to a potential function in aging. Further
studies need to be carried out to unravel the details how 5hmC in mito-
chondria is converted.
5. DNA demethylation in neurodevelopment disorders
The dynamic and unique features of 5hmC in differential tissues
and at different ages prompt the investigation of its potential roles
in diseases. Several studies strongly indicate the dysregulation of
5hmC could be involved in multiple diseases including cancer and neu-
rological disorders including neurodevelopmental disorders such as
Rett syndrome and Autism, and neurodegenerative diseases including
Huntington's disease and Alzheimer's disease (Table 1).
MeCP2, the gene commonly dysregulated in Rett syndrome, binds to
methylated DNA and represses gene expression. Surprisingly, it was
found that MeCP2 also served as a reader for 5hmC in brain [47]. The
overlapping of readers for 5hmC and 5mCmakes the story complicated
but more intriguing. Our previous study revealed a reverse correlation
between Rett syndrome gene MeCP2 and 5hmC level, suggesting that
MeCP2 bind to 5mC blocking the conversion of 5mC to 5hmC [20]. We
identiﬁed stable and dynamic differential hydroxymethylated regions
(DhMRs) between adult and aged stages. Interestingly, MeCP2 absence
speciﬁcally decreased 5hmC signal of those dynamic DhMRs without
effecting on stable DhMRs [20]. Another detailed studyunexpectedly re-
vealed thatMeCP2 could bind to 5hmCmodiﬁed loci in the neuronal ge-
nome with similar afﬁnity as 5mC [30]. One mutated form of MeCP2,
Fig. 1. The schematic illustration of the relationship of DNA methylation and demethylation and gene expression. A. DNA methylation in promoter region leads to the repression of gene
expression. B. Tet gene members convert 5mC to 5hmC in distinct genomic regions, which potentially involves in the regulation of gene expression.
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binding to 5hmC [30]. These results indicate that 5hmC-mediated
DNA demethylation pathway could be involved in the pathogenesis of
Rett syndrome.
Autism is a developmental neurological disorder, and is character-
ized by deﬁcits in social interactions, communication skills, and unusual
repetitive behaviors. The etiology of autism is very complicated and the
exact mechanism remains unclear. Past studies have revealed that
epigenetic factors such as DNAmethylation could contribute to autism.
Fragile X syndrome is the most common monogenic causes of autism
spectrum disorders. 5hmC highly correlated with neurodevelopment
genes and identiﬁed DhMRs in fetus and adult human cerebellum
showed a signiﬁcant overlapping with genes, including some autism
candidate genes such as Shank3, Nlgn3 and Tsc2 [39]. Genome-wide
proﬁling of 5hmC also reveals that 5hmC is highly enriched in
synapse-related, fragile X mental retardation protein (Fmrp) targeted,
and autism-related genes [39,40], suggesting a potential role of 5hmC
in autism.
Speciﬁcally, the increased 5hmC and decreased 5mC were detected
in the promoters of autism spectrum disorders (ASD) candidate genes
including glutamic acid decarboxylase-67 (Gad1), -65 (Gad2) and
Reelin (Reln) in the cerebella of ASD patients [48]. It is of interesting
to note that in ASD cases Tet1 transcript level and its binding to Gad1
and Reln promoters both increased [48]. Consistently, 5hmC enriched
at the promoters of Gad1 and Reln. Meanwhile, MeCP2 also displayed
higher binding to the promoters of Gad1 and Reln in ASD cerebella tis-
sues [48]. Therefore, these results supported a hypothesis that the en-
richment of 5hmC/5mC ratios at some speciﬁc gene domains such as
promoters, by Tet1, could enhance the binding of MeCP2 to distinct ge-
nomic regions, and then inhibited the expression of target genes in ASD
cerebella.Table 1
The differential alteration of 5hmC in neurological disorders.
Diseases The alteration of 5hmC Reference
Autism
(Autism spectrum disorders)
Enrichment on autism related genes. [39,40,48]
Rett syndrome Global decrease in the genome. [20]
Angelman syndrome Global increase in the genome. [20]
Fragile X syndrome (FXS) Enriching in FXS related genes. [39]
Alzheimer's disease (AD) Decrease or increase in the genome. [50–54]
Huntington's disease (HD) Global decrease. [49]6. DNA demethylation in neurodegenerative diseases
Huntington disease (HD) is a serious neurodegenerative disorder,
found to be an autosomal dominant genetic disease, characterized by
chorea, cognitive decline and psychiatric abnormalities. It is caused by
the abnormal expression of CAG repeat, which has 36 or more repeats
in HTT (Huntington protein) of HD patients. In transgenic HD mice,
the global level of 5hmC signiﬁcantly decreased in both striatum and
cortex relative to age-matched wild-type mice [49]. High-throughput
sequencing data showed that 5hmC was enriched in gene bodies and
depleted in intergenic regions [49]. Although the overall distribution
patterns were not affected, 747 DhMRs (49 up- and 698 down-
regulated) correlating to 30 and 406 genes, and 362 DhMRs (38 up-
and 324 down-regulated) corresponding to 28 and 171 genes, were
identiﬁed in transgenic striatum and cortex, respectively [49]. These
DhMR-associated genes displayed a good correlation with glutamate
receptor/calcium signaling/dopamine signaling/neuronal Creb signaling
pathways, which have been previously implicated in HD pathogenesis.
These results suggested that abnormal 5hmC could be involved in the
pathogenesis and progression of HD through dysregulating gene ex-
pression. Adora2a (Adenosine A2A receptor, A2AR) is a G-protein
coupled receptor, and its expression is severely reduced HD patients
and mice. The Adora2a protein level was abnormally reduced in puta-
men and caudate nucleus from an early stage of the HD patient's
brain. Interestingly, the 5' UTR of Adora2a displayed an increased 5mC
level but decreased 5hmC [50]. Together these studies highlight a role
of 5hmC in HD.
Alzheimer's disease (AD) is the most common neurodegenerative
disease which is characterized by a progressive decline in cognitive
functions and the loss of neuronal cells, and the presence of neuroﬁbril-
lary tangles (NFTs) and amyloid beta (Aβ) plaques in the cortex. The ex-
istence of 5hmC, 5fC and 5caC was revealed in brain, and a signiﬁcant
decrease of 5hmC levels was observed in all three hippocampal subre-
gions, entorhinal cortex and cerebellum of AD cases [51,52]. Moreover,
a negative relationship between 5hmC level and amyloid plaque loading
was also identiﬁed in the hippocampus [51]. However, other studies
found that in the hippocampus/parahippocampal gyrus of preclinical
AD and late-stage AD, 5hmC levels showed signiﬁcantly increase in
the middle frontal gyrus and the middle temporal gyrus of AD patients
[53,54]. Interestingly, the levels of 5fC and 5caC decreased [54]. The dis-
crepancybetween studies could be due tomultiple factors. Onepossibil-
ity is brain sampling, and another possibility could be the stage of AD.
Furthermore, all these studies only used immunostaining method and
350 W. Sun et al. / Genomics 104 (2014) 347–351studied global level of 5hmC. Other technologies such as liquid
chromatography–mass spectrometry and next-generation sequencing
are required to clarify the change of 5hmC in AD and its relationship
with Aβ deposition.
7. Conclusion and perspective
Past studies have indicated that 5hmC does not merely serve as a
DNA demethylation intermediate but also functions as a stable epige-
netic mark. 5hmC enriches in gene bodies, promoters, and transcription
factor binding sites and mounting evidence suggest roles of 5hmC in
regulating gene expression and controlling cell identity. The dysregula-
tion of 5hmC levels may lead to neurological diseases including
neurodevelopment and neurodegenerative diseases. These discoveries
collectively provide new insights in understanding the function of this
epigenetic modiﬁcation including DNA demethylation in brain. Despite
these progresses, our understanding about the function of 5hmC in
brain is very limited. Future studies need to address several important
questions regarding the function of 5hmC (in brain). The current evi-
dencesmainly indicate a correlative relationship between5hmCenrich-
ment and gene expression. In order to allow better understanding the
function of 5hmC, it is necessary to provide more direct proof showing
the function of 5hmC in gene expression. Pertinent questions remain re-
garding the exact functions of 5hmC in the brain, how theDNA demeth-
ylation pathway interacts with particular signaling pathways, and
indeed which pathways these may be in order to further investigate
thepotential role of this epigeneticmodiﬁcation in disease pathogenesis
in the brain. As a long-term goal, could we target speciﬁc 5hmC modi-
ﬁed loci to treat neurological disorders and then identify novel thera-
peutic strategy? Collectively these and future studies will advance our
understanding about the function of 5hmC.
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